Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2020

June 2020 | 260 pages | ID: RF4C13F7A72EN
Global Markets Direct

Abstracts

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa - Pipeline Review, H1 2020, provides an overview of the Retinitis Pigmentosa (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinitis Pigmentosa (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 17, 1, 1, 37 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 11 molecules, respectively.
Retinitis Pigmentosa (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Retinitis Pigmentosa (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Retinitis Pigmentosa (Retinitis) - Overview
Retinitis Pigmentosa (Retinitis) - Therapeutics Development
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
Retinitis Pigmentosa (Retinitis) - Drug Profiles
Retinitis Pigmentosa (Retinitis) - Dormant Projects
Retinitis Pigmentosa (Retinitis) - Discontinued Products
Retinitis Pigmentosa (Retinitis) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Allegro Ophthalmics LLC, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Ltd, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Alpine Biotherapeutics Corp, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Ankar Pharma SL, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Biogen Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Brighton Biotech Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Casebia Therapeutics, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Copernicus Therapeutics Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by DTx Pharma Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Pipeline by Editas Medicine Inc, H1 2020
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2020
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Molecular Therapeutics Inc
Allegro Ophthalmics LLC
Allergan Ltd
Alpine Biotherapeutics Corp
Amgen Inc
Ankar Pharma SL
Applied Genetic Technologies Corp
Biogen Inc
Brighton Biotech Inc
Casebia Therapeutics
Copernicus Therapeutics Inc
Dompe Farmaceutici SpA
DTx Pharma Inc
Editas Medicine Inc
Emerald Organic Products Inc
Endogena Therapeutics Inc
EyePoint Pharmaceuticals Inc
Eyestem Research Pvt Ltd
Eyevensys SAS
GenSight Biologics SA
Grupo Ferrer Internacional SA
Horama SA
ID Pharma Co Ltd
IVERIC bio Inc
jCyte Inc
Kubota Vision Inc
Kyoto Drug Discovery & Development Co Ltd
Lineage Cell Therapeutics Inc
MeiraGTx Holdings Plc
MimeTech Srl
Miragen Therapeutics Inc
Mireca Medicines GmbH
NanoScope Technologies LLC
Nanovector srl
Novartis AG
Ocugen Inc
OiDE OptoEye Inc
OliX Pharmaceuticals Inc
ONL Therapeutics Inc
OptiKira LLC
Oxford BioMedica Plc
Precision Biosciences Inc
Profarma
ProQR Therapeutics NV
PYCTX Ltd
Recursion Pharmaceuticals Inc
ReNeuron Group Plc
Retinagenix LLC
Rznomics Inc
SanBio Company Limited
SparingVision SAS
Staidson BioPharma Inc
Sumitomo Dainippon Pharma Co Ltd
Wave Life Sciences Ltd